The fullerenes—C60 and its derivatives in particular—have been lauded for three decades now as having revolutionary potential for next-generation medical applications. These span therapeutics (e.g. enzyme inhibition and photodynamic therapy for treating cancers) and diagnostics (e.g. improved contrast agents for magnetic resonance imaging). But translating this potential beyond academic research studies and into scaled-up production and clinical practice has proved far more elusive than the much-sought-after widespread industrial adoption of graphene.In this talk I will first outline why the fullerenes do indeed offer such promise in these clinical application areas, before providing an exploration of many of the intersecting factors that have contributed to making the clinical translation of fullerene-based therapeutics and diagnostics such a seemingly insurmountable barrier up to this point. These factors include: A uniquely multi-dimensional chemical design space when considering fullerene size and both exohedral and endohedral functionalisation possibilities;The relationship of the above with understanding functionality and safety in vivo;Regulatory requirements pertaining to the above;The presence of unregulated fullerene-based products in the beauty and wellness sector;The fuzzy borderlands between science and pseudoscience that much of the narrative around fullerenes occupies;Loss of funding momentum;Lack of industrial bridges between materials manufacturers and technology developers. After characterising the state of affairs in this way, I will offer some specific suggestions for hope and opportunity as we move into a world where synthesis and testing bottlenecks can be overcome with the help of artificial intelligence and automation, and increased awareness of the diverse properties of different types of nanomaterials changes the regulatory and industrial landscapes. Thus, I hope to provide a case study of how one family of carbon nanomaterials could finally realise its promise of advancing medicine in the Industry 4.0 era.
Read full abstract